Multicentre multi-device hybrid imaging study of coronary artery disease: results from the EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of Ischaemic Heart Disease (EVINCI) hybrid imaging population

AIMS: Hybrid imaging provides a non-invasive assessment of coronary anatomy and myocardial perfusion. We sought to evaluate the added clinical value of hybrid imaging in a multi-centre multi-vendor setting. METHODS AND RESULTS: Fourteen centres enrolled 252 patients with stable angina and intermediate (20-90%) pre-test likelihood of coronary artery disease (CAD) who underwent myocardial perfusion scintigraphy (MPS), CT coronary angiography (CTCA), and quantitative coronary angiography (QCA) with fractional flow reserve (FFR). Hybrid MPS/CTCA images were obtained by 3D image fusion. Blinded core-lab analyses were performed for CTCA, MPS, QCA and hybrid datasets. Hemodynamically significant CAD was ruled-in non-invasively in the presence of a matched finding (myocardial perfusion defect co-localized with stenosed coronary artery) and ruled-out with normal findings (both CTCA and MPS normal). Overall prevalence of significant CAD on QCA (>70% stenosis or 30-70% with FFR 640.80) was 37%. Of 1004 pathological myocardial segments on MPS, 246 (25%) were reclassified from their standard coronary distribution to another territory by hybrid imaging. In this respect, in 45/252 (18%) patients, hybrid imaging reassigned an entire perfusion defect to another coronary territory, changing the final diagnosis in 42% of the cases. Hybrid imaging allowed non-invasive CAD rule-out in 41%, and rule-in in 24% of patients, with a negative and positive predictive value of 88% and 87%, respectively. CONCLUSION: In patients at intermediate risk of CAD, hybrid imaging allows non-invasive co-localization of myocardial perfusion defects and subtending coronary arteries, impacting clinical decision-making in almost one every five subjects

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Efecto del calcio sobre la toxicidad aguda de aluminio en alevines de trucha arcoiris (Oncorhynchus mykiss) expuestos en aguas de diferente pH

En la producción de alevines de salmón de la región de la Araucanía (sur de Chile) se presentan importantes eventos de mortalidad aguda sin rasgos patológicos aparentes. El problema se focaliza en ejemplares de 0,2 a 1 g y las causas apuntan a procesos de acidificación del pH del agua y a la presencia de ciertos metales pesados, entre los cuales destaca el aluminio, que alcanza concentraciones más allá de los rangos de tolerancia de los peces. La información científica indica que concentraciones de 5 mg Ca L-1 en el afluente son suficientes para mantener a salvo los peces del efectos tóxico del aluminio. Sin embargo, los problemas en la producción de alevines de salmón indican que se requiere un mayor conocimiento científico y evidencia experimental que soporte el desarrollo de procesos y tecnologías para el tratamiento de los afluentes de las pisciculturas chilenas. En este trabajo se evaluó el efecto de cuatro concentraciones de calcio (0, 5, 10 y 20 mg Ca L-1) sobre la toxicidad aguda de 500 μg Al L-1 en alevines de trucha arcoiris (Oncorhynchus mykiss) de 0,1 g en agua de cultivo a pH 5, 6 y 7. El objetivo del trabajo fue determinar la dosis de calcio que reduce la toxicidad aguda de aluminio y los tiempos mínimos de reacción que podrían disponer los piscicultores para tomar medidas preventivas ante una concentración aguda de aluminio en el agua de cultivo. Los resultados indican que antes de 8 h de exposición a una concentración tóxica de aluminio los piscicultores deberían asegurar en el agua de cultivo una dosis superior a 10 mg Ca L-1 y un pH >6 como medida remedial para reducir el efecto de intoxicación aguda causada por aluminio

Crecimiento de juveniles de congrio colorado Genypterus chilensis en condiciones de cultivo

El congrio colorado Genypterus chilensis (Guichenot, 1848) es un pez altamente demandado por el mercado chileno. Las capturas han disminuido y mantenido bajo 1.000 ton anuales en la década 2000-2010 con un precio de US$7 kg-1. El objetivo de este trabajo fue evaluar el crecimiento de juveniles de primera generación producida de padres silvestres en condiciones de cultivo. Se estimó el crecimiento de 128 juveniles durante cinco meses en el hatchery del CIMARQ, Valparaíso, Chile, distribuidos en cinco grupos de talla en estanques con agua marina (35 g L-1) y rango de temperatura de 12-14°C. Los pesos promedios iniciales variaron desde el grupo menor de 4 g (11 cm) al mayor de 23 g (18 cm). Estos fueron alimentados con pellet comercial para peces marinos. Se midió mensualmente la longitud total (cm), peso (g) y se estimó sus promedios, porcentaje de crecimiento en peso, tasa de crecimiento específico, coeficiente de crecimiento termal y factor de conversión. A los cinco meses el grupo menor alcanzó un peso promedio de 16 ± 7 g (16 ± 2 cm) y el mayor 75 ± 17 g (27 ± 6 cm). Los pesos promedios mensuales se ajustaron con R² = 0,9 a las ecuaciones P = 3,845e0,300t y P = 20,63e0,240t. Los factores de conversión fluctuaron entre 8,6 y 0,3 al mes 5 para el grupo menor y de 0,6 a 0,2 para el mayor. Si se proyecta el crecimiento desde el peso inicial de 4 y 23 g hasta el peso de cosecha de 2 kg, éste se obtendría entre 26 y 18 meses para los grupos menor y mayor respectivamente

A New Integrated Clinical-Biohumoral Model to PredictFunctionally Significant Coronary Artery Disease inPatients With Chronic Chest Pain

BACKGROUND: In patients with chronic angina-like chest pain, the probability of coronary artery disease (CAD) is estimated by symptoms, age, and sex according to the Genders clinical model. We investigated the incremental value of circulating biomarkers over the Genders model to predict functionally significant CAD in patients with chronic chest pain. METHODS: In 527 patients (60.4 years, standard deviation, 8.9 years; 61.3% male participants) enrolled in the European Evaluation of Integrated Cardiac Imaging (EVINCI) study, clinical and biohumoral data were collected. RESULTS: Functionally significant CAD-ie, obstructive coronary disease seen at invasive angiography causing myocardial ischemia at stress imaging or associated with reduced fractional flow reserve (FFR < 0.8), or both-was present in 15.2% of patients. High-density lipoprotein (HDL) cholesterol, aspartate aminotransferase (AST) levels, and high-sensitivity C-reactive protein (hs-CRP) were the only independent predictors of disease among 31 biomarkers analyzed. The model integrating these biohumoral markers with clinical variables outperformed the Genders model by receiver operating characteristic curve (ROC) (area under the curve [AUC], 0.70 [standard error (SE), 0.03] vs 0.58 [SE, 0.03], respectively, P < 0.001) and reclassification analysis (net reclassification improvement, 0.15 [SE, 0.07]; P = 0.04). Cross-validation of the ROC analysis confirmed the discrimination ability of the new model (AUC, 0.66). As many as 56% of patients who were assigned to a higher pretest probability by the Genders model were correctly reassigned to a low probability class (< 15%) by the new integrated model. CONCLUSIONS: The Genders model has a low accuracy for predicting functionally significant CAD. A new model integrating HDL cholesterol, AST, and hs-CRP levels with common clinical variables has a higher predictive accuracy for functionally significant CAD and allows the reclassification of patients from an intermediate/high to a low pretest likelihood of CAD

Overview of mitral regurgitation in Europe: results from the European Registry of mitral regurgitation (EuMiClip)

AIMS: To determine the prevalence of mitral regurgitation (MR) in a large cohort of consecutive patients undergoing clinically indicated echocardiography and to examine the distribution of primary and secondary MR. METHODS AND RESULTS: All patients undergoing an echocardiographic study in 19 European centres within a 3-month period were prospectively included. MR assessment was performed as recommended by the European Association of Cardiovascular Imaging (EACVI). MR was classified according to mechanism as primary or secondary and aetiologies were reported. A total of 63 463 consecutive echocardiographic studies were reviewed. Any degree of MR was described in 15 501 patients. Concomitant valve disease of at least moderate grade was present in 28.5% of patients, being tricuspid regurgitation the most prevalent. In the subgroup of moderate and severe MR (n\u2009=\u20093309), 55% of patients had primary MR and 30% secondary MR. Both mechanisms were described in 14% of the studies. According to Carpentier's classification, 26.7% of MR were classified as I, 19.9% of MR as II, 22.4% of MR as IIIa, and 31.1% of MR as IIIb. CONCLUSION: To date, this is the largest echocardiography-based study to analyse the prevalence and aetiology distribution of MR in Europe. The burden of secondary MR was higher than previously described, representing 30% of patients with significant MR. In our environment, degenerative disease is the most common aetiology of primary MR (60%), whereas ischaemic is the most common aetiology of secondary MR (51%). Up to 70% of patients with severe primary MR may have a Class I indication for surgery. However, the optimal therapeutic approach for secondary MR remains uncertain

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

N/